These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 23385635)
1. Alteration of proteomic profiles in PBMC isolated from patients with Fabry disease: preliminary findings. Cigna D; D'Anna C; Zizzo C; Francofonte D; Sorrentino I; Colomba P; Albeggiani G; Armini A; Bianchi L; Bini L; Duro G Mol Biosyst; 2013 Jun; 9(6):1162-8. PubMed ID: 23385635 [TBL] [Abstract][Full Text] [Related]
2. Differentially expressed proteins in ER+ MCF7 and ER- MDA- MB-231 human breast cancer cells by RhoGDI-α silencing and overexpression. Hooshmand S; Ghaderi A; Yusoff K; Thilakavathy K; Rosli R; Mojtahedi Z Asian Pac J Cancer Prev; 2014; 15(7):3311-7. PubMed ID: 24815488 [TBL] [Abstract][Full Text] [Related]
3. Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Nowak A; Mechtler TP; Desnick RJ; Kasper DC Mol Genet Metab; 2017; 120(1-2):57-61. PubMed ID: 27773586 [TBL] [Abstract][Full Text] [Related]
4. Detection of blood Gb3 deposits as a new tool for diagnosis and therapy monitoring in patients with classic Fabry disease. Üçeyler N; Böttger J; Henkel L; Langjahr M; Mayer C; Nordbeck P; Wanner C; Sommer C J Intern Med; 2018 Oct; 284(4):427-438. PubMed ID: 29974530 [TBL] [Abstract][Full Text] [Related]
11. Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy. Heo SH; Kang E; Kim YM; Go H; Kim KY; Jung JY; Kang M; Kim GH; Kim JM; Choi IH; Choi JH; Jung SC; Desnick RJ; Yoo HW; Lee BH J Med Genet; 2017 Nov; 54(11):771-780. PubMed ID: 28835480 [TBL] [Abstract][Full Text] [Related]
12. Globotriaosylceramide-induced reduction of K Rickert V; Kramer D; Schubert AL; Sommer C; Wischmeyer E; Üçeyler N Exp Neurol; 2020 Feb; 324():113134. PubMed ID: 31778662 [TBL] [Abstract][Full Text] [Related]
13. Characterization of the plasma proteomic profile of Fabry disease: Potential sex- and clinical phenotype-specific biomarkers. López-Valverde L; Vázquez-Mosquera ME; Colón-Mejeras C; Bravo SB; Barbosa-Gouveia S; Álvarez JV; Sánchez-Martínez R; López-Mendoza M; López-Rodríguez M; Villacorta-Argüelles E; Goicoechea-Diezhandino MA; Guerrero-Márquez FJ; Ortolano S; Leao-Teles E; Hermida-Ameijeiras Á; Couce ML Transl Res; 2024 Jul; 269():47-63. PubMed ID: 38395389 [TBL] [Abstract][Full Text] [Related]